KALA has been the topic of a number of other research reports. Jefferies Financial Group assumed coverage on Kala Pharmaceuticals in a research note on Thursday, March 14th. They issued a buy rating and a $15.00 target price on the stock. HC Wainwright reissued a buy rating and issued a $15.00 target price on shares of Kala Pharmaceuticals in a research note on Thursday, December 27th. Zacks Investment Research cut Kala Pharmaceuticals from a buy rating to a hold rating in a research note on Tuesday, January 22nd. Wedbush set a $51.00 target price on Kala Pharmaceuticals and gave the company a buy rating in a research note on Wednesday, January 16th. Finally, ValuEngine cut Kala Pharmaceuticals from a buy rating to a hold rating in a research note on Friday, December 21st. Three analysts have rated the stock with a hold rating and five have assigned a buy rating to the stock. The company currently has a consensus rating of Buy and an average target price of $20.58.
Kala Pharmaceuticals stock opened at $7.92 on Tuesday. Kala Pharmaceuticals has a fifty-two week low of $4.03 and a fifty-two week high of $17.53. The company has a debt-to-equity ratio of 0.67, a quick ratio of 10.17 and a current ratio of 10.41.
Kala Pharmaceuticals (NASDAQ:KALA) last released its quarterly earnings results on Monday, March 11th. The company reported ($0.75) earnings per share for the quarter, missing the consensus estimate of ($0.52) by ($0.23). As a group, equities analysts anticipate that Kala Pharmaceuticals will post -2.83 earnings per share for the current fiscal year.
A number of institutional investors and hedge funds have recently added to or reduced their stakes in KALA. JPMorgan Chase & Co. increased its stake in Kala Pharmaceuticals by 37.4% in the third quarter. JPMorgan Chase & Co. now owns 160,080 shares of the company’s stock valued at $1,580,000 after acquiring an additional 43,599 shares during the last quarter. BlackRock Inc. increased its stake in Kala Pharmaceuticals by 16.8% in the third quarter. BlackRock Inc. now owns 1,105,361 shares of the company’s stock valued at $10,910,000 after acquiring an additional 158,883 shares during the last quarter. Virtu Financial LLC bought a new position in shares of Kala Pharmaceuticals during the third quarter valued at about $200,000. Dimensional Fund Advisors LP bought a new position in shares of Kala Pharmaceuticals during the third quarter valued at about $1,551,000. Finally, Standard Life Aberdeen plc bought a new position in shares of Kala Pharmaceuticals during the third quarter valued at about $420,000. 67.20% of the stock is currently owned by institutional investors and hedge funds.
About Kala Pharmaceuticals
Kala Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of therapies using its proprietary nanoparticle-based Mucus Penetrating Particles (MPP) technology for the treatment of eye diseases. The company's lead product candidate is KPI-121 0.25% which has completed two Phase III clinical trials for the treatment of temporary relief of the signs and symptoms of dry eye disease; INVELTYS which has completed two Phase III clinical trials for the treatment of inflammation and pain following ocular surgery; and KPI-285, a MPP receptor tyrosine kinase inhibitor program, which is in preclinical studies for the treatment of retinal diseases.
Further Reading: What is Cost of Goods Sold (COGS)?
Receive News & Ratings for Kala Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kala Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.